Information Provided By:
Fly News Breaks for September 10, 2019
AVEO
Sep 10, 2019 | 12:35 EDT
Piper Jaffray analyst Edward Tenthoff raised his price target for Aveo Pharmaceuticals to $4 from $3 after the company announced that tivozanib's overall survival hazard ratio was 0.99 as of a planned analysis on August 15. The analyst continues to anticipate launch in the 3rd and 4th-line renal cell carcinoma setting in 2021. The analyst reduced his tivozanib discount rate and keeps an Overweight rating on shares of Aveo Pharmaceuticals.
News For AVEO From the Last 2 Days
There are no results for your query AVEO
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.